• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600085.SS
Share

Beijing Tongrentang Co., Ltd Stocks

CN¥ 23.33Last Updated 11.09.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

CN¥ 4.93B

CN¥ 23.33
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Somewhat favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Beijing Tongrentang Co., Ltd engages in the production and sale of traditional Chinese medicine preparations in China and internationally. The company offers various product dosage forms, such as pills, powders, medicated wines, capsules, oral liquids, and drop pills. Its products are used for cardiovascular, cerebrovascular, gynecology, heat-clearing, respiratory system, nourishing and calming, digestive, pediatrics, wind-dispelling and dampness removing, orthopedics, facial features, dermatological surgery, mental health, and food and beverages applications. The company was founded in 1997 and is based in Beijing, China. Beijing Tongrentang Co., Ltd operates as a subsidiary of China Beijing Tong Ren Tang Group Co. Ltd.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 600085.SS is 36.5 and suggests 52.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.09.2026 17:37

Inflation in the U.S. in August came in slightly above expectations. What can we expect from the Fed now?

11.09.2026 17:24

"A Recipe for Volatility": Why BofA Sees Risks in Market Calm

11.09.2026 15:00

Uber's CEO Invested $10 Million in the Company's Shares, Which Had Fallen in Price

11.09.2026 13:30

An investor from "Shorting" advised buying wine amid the dollar's decline

11.09.2026 13:11

Diesel prices in the U.S. have exceeded $6 per gallon for the first time in history

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026